NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Pfizer
»11/12/2009 [Company watch]
Pfizer, Crown Bioscience in R&D tie up for Asian Cancers

Pfizer (PFE) and Crown Bioscience, have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers is said to represent an important unmet medical need as well as a significant market opportunity.

 
Pfizer (PFE) and Crown Bioscience, have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers is said to represent an important unmet medical need as well as a significant market opportunity. Under the terms of this agreement, Crown will receive an upfront payment and research funding, as well as milestone payments based on the achievement of pre-clinical and clinical goals. The companies will work together to discover and advance multiple candidates for clinical development. The work will take place at Crown’s new research facility located in Taicang (near Shanghai), China. “I am delighted to be collaborating with Pfizer’s exceptional oncology group,” says Mr Alex Wu, CEO, Crown. “I am also very happy that Pfizer is focusing on and dedicating resources to address a very important unmet medical need for the Asian populations. This new collaboration extends an already very successful partnership between Crown and Pfizer and further demonstrates Crown’s commitment to becoming an outstanding cancer research company in Asia.” “We are delighted to be working closely with Crown to implement a focused drug discovery and development strategy relating to the tumors most prevalent in the Asia region,” says Mr Neil Gibson, Chief Scientific Officer, Pfizer’s Oncology Research Unit. “By doing so, we believe we can capitalize on the oncology expertise of Crown and enhance our ability to bring novel therapeutics to the marketplace that will benefit cancer patients in Asia.”

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.